Arrowstreet Capital’s GSK GSK Stock Holding History

Arrowstreet Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$89.5M	Sell	1,621,397 -643,789	-28%	-$34.9M	0.05%	332
2025 Q4	$111M	Buy	+2,265,186	New	+$106M	0.07%	276
2025 Q2	–	Sell	-1,493,545	Closed	-$57.9M	–	1984
2025 Q1	$57.9M	Buy	1,493,545 +1,275,289	+584%	+$46.7M	0.05%	342
2024 Q4	$7.38M	Sell	218,256 -3,651,243	-94%	-$131M	0.01%	913
2024 Q3	$212M	Buy	3,869,499 +1,290,752	+50%	+$52.8M	0.18%	111
2024 Q2	$99.3M	Buy	2,578,747 +472,475	+22%	+$19.9M	0.09%	195
2024 Q1	$90.3M	Sell	2,106,272 -2,713,681	-56%	-$112M	0.08%	212
2023 Q4	$179M	Sell	4,819,953 -2,982,809	-38%	-$107M	0.19%	111
2023 Q3	$283M	Sell	7,802,762 -401,915	-5%	-$14.3M	0.34%	65
2023 Q2	$292M	Sell	8,204,677 -2,632,137	-24%	-$94.4M	0.36%	69
2023 Q1	$386M	Sell	10,836,814 -3,207,536	-23%	-$112M	0.5%	50
2022 Q4	$494M	Buy	14,044,350 +5,998,831	+75%	+$200M	0.69%	33
2022 Q3	$237M	Buy	8,045,519 +53,828	+0.7%	+$2.04M	0.35%	83
2022 Q2	$435M	Buy	7,991,691 +294,595	+4%	+$16.3M	0.62%	36
2022 Q1	$419M	Buy	7,697,096 +1,889,819	+33%	+$103M	0.52%	48
2021 Q4	$320M	Buy	5,807,277 +2,826,147	+95%	+$147M	0.39%	57
2021 Q3	$142M	Buy	2,981,130 +1,543,476	+107%	+$77.5M	0.18%	127
2021 Q2	$71.6M	Sell	1,437,654 -768,440	-35%	-$36.9M	0.09%	251
2021 Q1	$98.4M	Sell	2,206,094 -3,604,693	-62%	-$164M	0.13%	154
2020 Q4	$267M	Buy	5,810,787 +2,634,859	+83%	+$121M	0.38%	50
2020 Q3	$149M	Sell	3,175,928 -191,138	-6%	-$9.58M	0.24%	74
2020 Q2	$172M	Buy	3,367,066 +1,005,384	+43%	+$51.6M	0.32%	53
2020 Q1	$112M	Sell	2,361,682 -1,047,274	-31%	-$55.9M	0.31%	55
2019 Q4	$200M	Sell	3,408,956 -586,956	-15%	-$32.6M	0.47%	40
2019 Q3	$213M	Sell	3,995,912 -389,530	-9%	-$20M	0.5%	48
2019 Q2	$219M	Sell	4,385,442 -3,791,584	-46%	-$190M	0.49%	55
2019 Q1	$427M	Buy	8,177,026 +1,372,258	+20%	+$68.6M	1.01%	18
2018 Q4	$325M	Buy	6,804,768 +2,443,129	+56%	+$120M	0.85%	22
2018 Q3	$219M	Buy	4,361,639 +4,287,559	+5,788%	+$218M	0.49%	52
2018 Q2	$3.73M	Buy	+74,080	New	+$3.73M	0.01%	590
2018 Q1	–	Sell	-574,273	Closed	-$25.5M	–	1210
2017 Q4	$25.5M	Buy	574,273 +326,753	+132%	+$15.1M	0.06%	273
2017 Q3	$12.6M	Buy	247,520 +23,499	+10%	+$1.19M	0.03%	342
2017 Q2	$12.1M	Sell	224,021 -4,661,024	-95%	-$248M	0.04%	329
2017 Q1	$257M	Buy	+4,885,045	New	+$248M	0.94%	17
2016 Q4	–	Sell	-3,624,276	Closed	-$195M	–	2003
2016 Q3	$195M	Sell	3,624,276 -1,007,674	-22%	-$55.3M	0.64%	30
2016 Q2	$251M	Buy	4,631,950 +3,876,888	+513%	+$204M	0.83%	18
2016 Q1	$38.3M	Buy	755,062 +694,262	+1,142%	+$34.6M	0.16%	143
2015 Q4	$3.07M	Sell	60,800 -2,534,002	-98%	-$129M	0.01%	679
2015 Q3	$125M	Buy	2,594,802 +1,792,864	+224%	+$93.3M	0.59%	34
2015 Q2	$41.8M	Buy	+801,938	New	+$45.2M	0.24%	111
2014 Q4	–	Sell	-1,704,552	Closed	-$97.9M	–	1265
2014 Q3	$97.9M	Sell	1,704,552 -1,469,744	-46%	-$90.1M	0.53%	42
2014 Q2	$212M	Sell	3,174,296 -2,199,665	-41%	-$149M	1.09%	20
2014 Q1	$359M	Buy	5,373,961 +3,449,966	+179%	+$233M	2.17%	1
2013 Q4	$128M	Sell	1,923,995 -2,546,236	-57%	-$165M	0.7%	31
2013 Q3	$280M	Sell	4,470,231 -3,703,138	-45%	-$238M	1.78%	4
2013 Q2	$511M	Buy	+8,173,369	New	+$519M	3.81%	1

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital's GSK Position: Q1 2026 in Review

Arrowstreet Capital reduced its GSK (GSK) stake by 28% in Q1 2026, selling an estimated $34.9M and leaving 1,621,397 shares worth $89.5M. The position accounts for 0.05% of the portfolio, ranked #332.

Arrowstreet Capital first reported a position in GSK in Q2 2013 and has held it in 46 quarters since. The position peaked at $511M in Q2 2013. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Arrowstreet Capital held 1,621,397 shares of GSK worth $89.5M as of Q1 2026.
Arrowstreet Capital sold 643,789 GSK shares in Q1 2026, an estimated $34.9M.
GSK made up 0.05% of Arrowstreet Capital's portfolio in Q1 2026, its #332 holding.
Arrowstreet Capital first reported a position in GSK in Q2 2013 and has held it in 46 quarters since.
Arrowstreet Capital's GSK position peaked at $511M in Q2 2013.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.